What is Zacks Research’s Forecast for Novartis Q4 Earnings?

Novartis AG (NYSE:NVS) – Analysts at Zacks Research dropped their Q4 2024 earnings per share estimates for Novartis in a research note issued to investors on Tuesday, November 12th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.76 per share for the quarter, down from their previous estimate of $1.86. The consensus estimate for Novartis’ current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis’ Q3 2025 earnings at $2.18 EPS, Q4 2025 earnings at $2.02 EPS, FY2025 earnings at $8.23 EPS, Q2 2026 earnings at $2.22 EPS and Q3 2026 earnings at $2.42 EPS.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The business had revenue of $12.82 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter in the prior year, the company posted $1.74 EPS.

Several other equities research analysts have also recently weighed in on the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $121.00 price objective (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Jefferies Financial Group lowered shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 3rd. Finally, Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and cut their target price for the company from $135.00 to $130.00 in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus price target of $121.50.

Novartis Stock Performance

Novartis stock opened at $103.06 on Friday. Novartis has a 1-year low of $92.35 and a 1-year high of $120.92. The firm has a market cap of $210.65 billion, a P/E ratio of 11.97, a P/E/G ratio of 1.50 and a beta of 0.58. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average of $113.14 and a 200-day moving average of $109.84.

Institutional Investors Weigh In On Novartis

Hedge funds have recently bought and sold shares of the business. Raymond James & Associates lifted its holdings in shares of Novartis by 1.3% during the second quarter. Raymond James & Associates now owns 536,607 shares of the company’s stock valued at $57,127,000 after purchasing an additional 6,767 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in Novartis in the second quarter worth $15,044,000. O Shaughnessy Asset Management LLC grew its stake in shares of Novartis by 6.5% in the first quarter. O Shaughnessy Asset Management LLC now owns 180,764 shares of the company’s stock worth $17,485,000 after acquiring an additional 11,080 shares during the last quarter. Integral Health Asset Management LLC increased its holdings in shares of Novartis by 33.3% during the second quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $31,938,000 after acquiring an additional 75,000 shares in the last quarter. Finally, Granite Bay Wealth Management LLC purchased a new position in shares of Novartis in the 2nd quarter worth about $854,000. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.